| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0005 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0005 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0006 |